Cargando…
Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
The COVID-19 pandemic has impacted every country in the world. With more than 400 million cases and more than 5.5 million deaths. The FDA either approved or authorized the emergency use for three vaccines against COVID-19. The treatment options of COVID-19 are very limited. Multiple complementary an...
Autores principales: | Abdelrahim, Maen, Esmail, Abdullah, Al Saadi, Noor, Zsigmond, Eva, Al Najjar, Ebtesam, Bugazia, Doaa, Al-Rawi, Hadeel, Alsaadi, Ayat, Kaseb, Ahmed O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022724/ https://www.ncbi.nlm.nih.gov/pubmed/35462919 http://dx.doi.org/10.3389/fphar.2022.848676 |
Ejemplares similares
-
Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022) -
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022) -
Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022) -
Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021) -
Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)